Trial Profile
Phase II Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 30 Jun 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 30 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2008 New trial record.